Nathan Pennell

Associate Professor

Cleveland Clinic

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Nathan Pennell is an Associate Professor at Cleveland Clinic in the United States. His research focuses on various aspects of lung cancer, particularly in the areas of novel therapies, radiomics, and patient-centered approaches. He has contributed to recent articles addressing immunotherapy development, genetic testing, and lung cancer screening initiatives.

Articles (9)

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (2)

Emil Lou

University of Minnesota

UNITED STATES

View details

ENRIQUETA FELIP

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nathan Pennell

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST

Clinical Nomogram Using Novel Computed Tomography–Based Radiomics Predicts Survival in Patients With Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy

Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States

Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer

The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator

Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al

MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations

Cases from the Immune‐Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade‐Induced Diabetes

Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening

Collaborators (2)

Emil Lou

ENRIQUETA FELIP

Make your next move.